The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway

The diabetes medication canagliflozin (Cana) is a sodium glucose cotransporter 2 (SGLT2) inhibitor acting by increasing urinary glucose excretion and thus reducing hyperglycaemia. Cana treatment also reduces body weight. However, it remains unclear whether Cana could directly work on adipose tissue....

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xuping, Liu, Qinhui, Li, Yanping, Tang, Qin, Wu, Tong, Chen, Lei, Pu, Shiyun, Zhao, Yingnan, Zhang, Guorong, Huang, Cuiyuan, Zhang, Jinhang, Zhang, Zijing, Huang, Ya, Zou, Min, Shi, Xiongjie, Jiang, Wei, Wang, Rui, He, Jinhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469612/
https://www.ncbi.nlm.nih.gov/pubmed/32835596
http://dx.doi.org/10.1080/21623945.2020.1807850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469612/
https://www.ncbi.nlm.nih.gov/pubmed/32835596
http://dx.doi.org/10.1080/21623945.2020.1807850

Ejemplares similares